PXD065556-1

PXD065556 is an original dataset announced via ProteomeXchange.

Title	Integrated Metabolomics and Proteomics Analysis Reveals the Mechanisms of Banxia-Xiexin Decoction in Colitis-Associated Colorectal Cancer
Description	Colitis-associated colorectal cancer (CAC), a subtype of colorectal cancer arising from chronic colonic inflammation, remains without specific therapeutic agents. Banxia-Xiexin decoction (BXD), a traditional Chinese medicine, is clinically used to treat gastritis and ulcerative colitis; however, its efficacy in CAC and associated mechanisms are not well understood. This study aimed to evaluate the therapeutic potential of BXD against CAC and explore its molecular mechanisms. A CAC mouse model was induced using azoxymethane/dextran sulfate sodium (AOM/DSS), and BXD was administered at vary-ing doses (0.95, 1.9, or 3.8 g/kg/day), alongside a sulfasalazine control. Therapeutic effica-cy was assessed by analyzing disease activity index, inflammatory markers, and histo-pathological changes. Additionally, 4D label-free proteomics and serum metabolomics were conducted to elucidate potential mechanisms. BXD significantly improved disease outcomes in CAC mice by reducing colonic inflammation and tumor hyperplasia, while lowering serum levels of TNF-α, IL-6, IL-1β, and IFN-γ. Metabolomic profiling suggested that BXD modulates valine, leucine, and isoleucine metabolism. Proteomic analysis re-vealed differentially expressed proteins (DEPs) enriched in complement and coagulation cascade pathways. Key DEPs (Fgg, Fgb, C3, and Cfh) were reversed by BXD treatment, which was confirmed at the mRNA level by qRT-PCR. In conclusion, BXD exerts protec-tive effects against CAC by regulating inflammatory responses and modulating amino acid metabolism and complement pathways. These findings provide novel insights into the pharmacological basis of BXD and support its potential clinical application in CAC therapy.
HostingRepository	PRIDE
AnnounceDate	2025-11-10
AnnouncementXML	Submission_2025-11-09_16:30:45.731.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	Xuelian Dong
SpeciesList	scientific name: Mus musculus (Mouse); NCBI TaxID: NEWT:10090;
ModificationList	No PTMs are included in the dataset
Instrument	timsTOF Pro 2

Revision	Datetime	Status	ChangeLog Entry
0	2025-06-27 02:56:26	ID requested
⏵ 1	2025-11-09 16:30:46	announced

10.2147/jir.s562302;

Chen Q, Wang M, Shi W, Liu Y, Wang L, Zhao Y, Qiu Z, Qiu Y, Dong X, Banxia-Xiexin Decoction Ameliorates Colitis-Associated Colorectal Cancer by Modulating Inflammatory Responses and the Complement and Coagulation Cascade Pathway. J Inflamm Res, 18():15135-15151(2025) [pubmed]

submitter keyword: Banxia-Xiexin decoction

colitis-associated colorectal cancer

serum metabolomics

proteomics

coagulation cascade

Xuelian Dong
contact affiliation	Changchun University of Chinese Medicine
contact email	dongxuelian1979@126.com
lab head
Xuelian Dong
contact affiliation	Changchun University of Chinese Medicine
contact email	dongxuelian1979@126.com
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2025/11/PXD065556

PRIDE project URI

• PRIDE
  1. PXD065556
     1. Label: PRIDE project
     2. Name: Integrated Metabolomics and Proteomics Analysis Reveals the Mechanisms of Banxia-Xiexin Decoction in Colitis-Associated Colorectal Cancer